Indications for the use of cytomegalovirus-seronegative blood products.
Preiksaitis
J K
JK
University of Alberta, Edmonton, Canada.
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D001803:Blood Transfusion / Q000592:standards; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007231:Infant, Newborn; D007962:Leukocytes / Q000382:microbiology; D008297:Male; D008954:Models, Biological; D009000:Monocytes / Q000382:microbiology; D009369:Neoplasms / Q000150:complications / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D015995:Prevalence; D012307:Risk Factors; D065227:Transfusion Reaction; D014775:Virus Activation
D000914:Antibodies, Viral